文献速递临床试验与 GCP医学人工智能与信息学

基于多阶段优化策略框架与去中心化临床试验系统优化癌症患者抑郁和焦虑的手机心理治疗:SMILE AGAIN项目随机对照试验方案

Optimization of smartphone psychotherapy for depression and anxiety among patients with cancer using the multiphase optimization strategy (MOST) framework and decentralized clinical trial system (SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience: SMILE AGAIN project): a protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-05-22

本研究基于多阶段优化策略(MOST)框架,采用平行组、多中心、开放、分层区组随机、全因子试验设计,评估心理社会教育、行为激活、自信训练和问题解决治疗四种成分对癌症患者抑郁和焦虑的疗效。所有参与者接受心理社会教育后随机分配其余三种成分的有无,主要结局为8周后手机电子患者报告的患者健康问卷-9(PHQ-9)总分。试验于2021年3月启动,预计2023年3月结束,旨在确定最有效的成分组合。

要点

  • 基于MOST框架的全因子试验可识别手机心理治疗包中最有效的成分及组合。
  • 所有参与者接受心理社会教育,并随机分配行为激活、自信训练和问题解决治疗的有无。
  • 主要结局为8周后手机电子患者报告的患者健康问卷-9(PHQ-9)总分。

核心结论

  • 该高效试验设计将识别手机心理治疗包中四种成分里最有效的成分和最有效的组合。
  • 若确定有效的心理治疗组合,可通过手机提供给难以方便到达医院或诊所的患者。

研究设计与样本

  • 基于多阶段优化策略(MOST)框架的平行组、多中心、开放、分层区组随机、全因子试验。
  • 四种实验成分:心理社会教育(PE)、行为激活(BA)、自信训练(AT)和问题解决治疗(PS)。
  • 分配序列集中维护,所有参与者接受PE后随机分配其余三种成分的有无。

主要发现

  • 主要结局为8周后以电子患者报告结局形式在患者智能手机上施测的患者健康问卷-9(PHQ-9)总分。
  • 试验于2021年3月启动,正在招募参与者,预计结束日期为2023年3月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer patients experience various forms of psychological distress. Their distress, mainly in the form of depression and anxiety, leads to poor quality of life, increased medical spending due to frequent visits, and decrease in treatment adherence. It is estimated that 30-50% among them would require support from mental health professionals: in reality, much less actually receive such support partly due to a shortage of qualified professionals and also due to psychological barriers in seeking such help. The purpose of the present study is to develop the easily accessible and the most efficient and effective smartphone psychotherapy package to alleviate depression and anxiety in cancer patients. METHODS: Based on the multiphase optimization strategy (MOST) framework, the SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience project (SMILE-AGAIN project) is a parallel-group, multicenter, open, stratified block randomized, fully factorial trial with four experimental components: psychosocial education (PE), behavioral activation (BA), assertion training (AT), and problem-solving therapy (PS). The allocation sequences are maintained centrally. All participants receive PE and then are randomized to the presence/absence of the remaining three components. The primary outcome of this study is the Patient Health Questionnaire-9 (PHQ-9) total score, which will be administered as an electronic patient-reported outcome on the patients' smartphones after 8 weeks. The protocol was approved by the Institutional Review Board of Nagoya City University on July 15, 2020 (ID: 46-20-0005). The randomized trial, which commenced in March 2021, is currently enrolling participants. The estimated end date for this study is March 2023. DISCUSSION: The highly efficient experimental design will allow for the identification of the most effective components and the most efficient combinations among the four components of the smartphone psychotherapy package for cancer patients. Given that many cancer patients face significant psychological hurdles in seeing mental health professionals, easily accessible therapeutic interventions without hospital visits may offer benefits. If an effective combination of psychotherapy is determined in this study, it can be provided using smartphones to patients who cannot easily access hospitals or clinics. TRIAL REGISTRATION: UMIN000041536, CTR. Registered on 1 November 2020 https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047301 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Uchida M, Furukawa TA, Yamaguchi T, et al. Optimization of smartphone psychotherapy for depression and anxiety among patients with cancer using the multiphase optimization strategy (MOST) framework and decentralized clinical trial system (SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience: SMILE AGAIN project): a protocol for a randomized controlled trial. Trials. 2023. PMID: 37217965. doi:10.1186/s13063-023-07307-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。